LXEO NASDAQ
Lexeo Therapeutics, Inc. Common Stock
1W: -5.0%
1M: -8.6%
3M: -33.4%
YTD: -70.1%
1Y: -68.9%
$2.87
+0.17 (+6.30%)
Pre-Market: $2.65 (-0.22, -7.67%)
Weekly Expected Move ±11.6%
$2
$2
$3
$3
$3
Credit Risk of going bust: lower than 56% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.6%), Lexeo Therapeutics, Inc. Common Stock would be worth roughly what it owes.
Total debt $6.8M against a stock market value of $235.6M.
Distance to default 5.69 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 72.0%; Altman Z'' 9.90. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.6%), Lexeo Therapeutics, Inc. Common Stock would be worth roughly what it owes.
Total debt $6.8M against a stock market value of $235.6M.
Distance to default 5.69 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 72.0%; Altman Z'' 9.90. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships2
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2024-04-22
Earliest Filing
2024-04-22
Latest Filing
partner: 2
Counterparties (Filed by LXEO)
2 relationshipsCompanies named in LXEO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Cornell University | — | partner | Granted exclusive and non-exclusive licenses for gene therapy patents and data regarding Friedreich's ataxia cardiomyopa | 2024-04-22 | View |
| Weill Cornell Medicine | — | partner | Conducted the Phase 1A trial generating data licensed to Lexeo and previously collaborated on the gene therapy candidate | 2024-04-22 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-29 | Acquisition/Disposition; Unregistered Equity Sales; Exhibits | Acquisition | View |
| 2026-09-22 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-08-12 | Earnings Release; Other Events; Exhibits | View | |
| 2026-06-29 | Shareholder Vote | View | |
| 2026-06-15 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-11 | Earnings Release; Other Events; Exhibits | View | |
| 2026-04-30 | Officer/Director Change | View | |
| 2026-03-30 | Earnings Release; Other Events; Exhibits | View | |
| 2026-02-05 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-27 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-12 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-17 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Unregistere | Agreement | View |
| 2025-10-07 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-14 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-06-30 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-27 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-07 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-03-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR